Consensus on precision medicine for metastatic cancers: a report from the MAP conference ((Molecular Analyses for Personalized medicine)

open access

 Table 1.

Summary of consensus items

 conclusion

The conclusion of this first consensus conference (2015) was that new technologies have convincing analytical validity and the use of small panels of biomarkers is required for optimal cancer care. Nevertheless, there is not yet sufficient evidence that using large gene panels improves patient outcome. Randomized trials are currently addressing this question. The next MAP consensus conference will be held in London, during 23–24 September 2016. Among many items, this new consensus will discuss which genomic alterations should be screened in patients with colon, prostate cancer and sarcoma, together with precision medicine for immunotherapeutics and models of implementation. Regarding this latter point, speakers will debate about whether one universal panel of genes should be implemented across diseases, or whether each disease should have its own panel.